Patent · US Active

Compositions and methods for inhibiting expression of the PCSK9 gene

US8222222B2 · kind B2 · utility

12Cited by
5References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 4, 2009
Grant dateJul 17, 2012
Priority date
Expiry dateApr 25, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3515
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.